To include your compound in the COVID-19 Resource Center, submit it here.

Dermira discontinues development of acne candidate

Dermira Inc. (NASDAQ:DERM) said olumacostat glasaretil (formerly DRM01) missed the co-primary endpoints in two double-blind, international Phase III trials to treat moderate to severe acne vulgaris. The company plans to discontinue development of the inhibitor of acetyl-Coenzyme A

Read the full 385 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE